首页> 美国卫生研究院文献>Journal of Clinical Medicine >COVID-19 and the Kidney: A Worrisome Scenario of Acute and Chronic Consequences
【2h】

COVID-19 and the Kidney: A Worrisome Scenario of Acute and Chronic Consequences

机译:Covid-19和肾脏:急性和慢性后果的令人担忧的情景

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acute kidney injury (AKI) is a common finding in patients with coronavirus disease 2019 (COVID-19) and has been associated with higher rates of death when compared to COVID-19 patients without kidney injury. Whereas the definitive pathogenesis of COVID-19-related AKI (CoV-AKI) is not clear, histopathologic evidence seems to point at multiple etiologies for the disease, including indirect and direct viral kidney injury. The high incidence of CoV-AKI, along with the aggressive clinical presentation of this entity, have increased the demands for kidney replacement therapies, rapidly overwhelming the supplies of healthcare systems even in major tertiary care centers. As a result, nephrologists have come up with alternatives to maximize the efficiency of treatments and have developed non-conventional therapeutic alternatives such as the implementation of acute peritoneal dialysis for critically ill patients. The long-term implications of CoV-AKI are yet unknown, though early studies suggest that around one third of the patients who survive will remain dependent on kidney replacement therapy. Nephrologists and healthcare workers need to be familiar with the clinical presentation and therapeutic challenges of CoV-AKI in order to develop strategies to mitigate the burden of the disease for patients, and for services providing kidney replacement therapies.
机译:急性肾损伤(AKI)是冠心病疾病2019年患者的常见发现(Covid-19),与没有肾损伤的Covid-19患者相比,与肾脏损伤的患者相比,与较高的死亡率有关。鉴于Covid-19相关的AKI(CoV-AKI)的最终发病机制尚不清楚,但组织病理学证据似乎指出了这种疾病的多种病因,包括间接和直接的病毒肾损伤。 CoV-AKI的高发病率以及该实体的侵略性临床介绍,增加了对肾脏替代疗法的需求,即使在主要的第三大教堂中也迅速地压倒了医疗保健系统的供应。因此,肾病学家已经提出了替代方案,以最大化治疗效率,并且已经开发出非常规治疗替代品,例如急性腹膜透析为危重患者的实施。 COV-AKI的长期影响尚不清楚,尽管早期研究表明,大约三分之一的生存患者将依赖于肾脏替代疗法。肾病学家和医疗保健工人需要熟悉COV-AKI的临床介绍和治疗挑战,以制定减轻患者疾病负担的策略,以及提供肾脏替代疗法的服务。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号